Me Dipali Ojha is a member of the Indian Bar association which recently initiated proceedings against Dr. Soumya Swaminathan Scientific Director of the WHO. In his debriefing, Dipali Ojha explains the details of the procedure and what to do next, as well as the situation in India.
In India, the Ministry of Health included ivermectin as part of the treatment of Covid19 as early as April 2021 and confirmed this on several occasions, including in its last recommendation. The Minister of Health therefore did not follow the advice of the WHO not to use ivermectin. India, after scientific review of the existing evidence, followed suit with Senegal, which had not followed the WHO advice on hydroxychloroquine with continuous use in combination with another molecule since March 2020. ” We do not blindly follow the WHO »Declared Professor Moussa Seydi, head of the infectious diseases department at Fann hospital in Dakar.
While several Indian states continue to prescribe ivermectin with success, WHO Chief Scientist Soumya Swaminathan, tweeted on May 10 that the UN agency advises against the use of the drug to treat patients with COVID-19, except in clinical trials. The tweet included a press release issued by the company that makes the drug, Merck, saying it had found no evidence to support the use of ivermectin in the treatment of COVID-19.
Safety and effectiveness are important when using any drug for a new indication. @WHO does not recommend the use of ivermectin for #COVID19, except in the context of clinical trials https://t.co/dSbDiW5tCW
– Soumya Swaminathan (@doctorsoumya) May 10, 2021
The action of Indian Bar
The Indian Bar’s response was straightforward – a formal notice before action demanding accountability from the scientific director of 51 pages which takes up the various arguments in favor of ivermectin and especially questions why the scientific director tweeted an old press release from Merck while on March 31, 2021 she herself issued a WHO opinion about ivermectin. This really raises questions.
Inflection point in India
A few weeks ago a group of Indian lawyers, whose sponsors are not yet identified, attacked the decision by the state of Goa to include ivermectin as part of the treatment against the Covid19 thus following national guidelines. The reasons given in the procedure were that the WHO had not approved the use of ivermectin.
The Government of Goa has therefore produced a memorandum in response confirming that WHO’s rationale for not using ivermectin is flawed. This brief is based on extensive evidence including the contradictory analysis of the WHO opinion made by the FLCCC of Dr Pierre Kory. It is therefore a first for a government to take a legal position in favor of early treatment.
Deputy Secretary (Health) Vikas Gaunekar said in an affidavit that
- Various studies carried out in different countries have shown that the drug has a positive effect on the prevention and treatment / cure of patients.
- The tablets have been shown to be effective in studies carried out in many countries, ”he said.
- Studies and reports endorsing ivermectin are available on the ivmmeta.com website.
- Some reports indicate that the World Health Organization’s analysis was flawed and that the death rate was very low in patients who received the tablets for early treatment or prophylaxis (preventive treatment)
The decision fell and the Bombay High Court confirms the use of ivermectin after review by a group of medical experts from the public and private sector on May 13, 2021.
Apart from the fact that the Deputy Secretary of Health recognizes the effectiveness of ivermectin as a treatment against Covid, medical experts from the public and the private sector have also confirmed it and the High Court has rendered a judgment in favor of this. treatment. It is indeed the recognition of this treatment in a country which has already generalized its use.
Dipali Ojha explains all this in detail in this uncompromising debriefing.
French version of the video debriefing